Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.20 USD
-0.07 (-5.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NKTR 1.20 -0.07(-5.51%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
Nektar initiated with bullish view at Rodman & Renshaw
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024